Entity

Time filter

Source Type

Castel Guelfo di Bologna, Italy

Vignoli M.,Veterinary Oncology Center | Barberet V.,Medical Imaging | Chiers K.,Laboratory of Veterinary Pathology | Duchateau L.,Ghent University | And 4 more authors.
European Journal of Cancer Prevention | Year: 2011

Several methods for obtaining specimens from abdominal organs have been described. Imaging-guided biopsy, particularly ultrasound-guided biopsy, is the most frequently used in clinical trials. The aim of this study was to evaluate the diagnostic quality of histological samples obtained with a manual biopsy device (Spirotome) on biopsies of the liver, spleen, and kidney, in fresh canine organs and in live animals in a clinical trial. The study was divided into two different parts, one using normal fresh canine organs with a total of 60 biopsies, 20 of liver, spleen, and kidney, respectively; and one on clinical patients, including 35 biopsied lesions in 28 animals (25 dogs and three cats) for a total of 95 biopsies. All the biopsy samples were considered satisfactory from canine cadavers, and all specimens were diagnostic in clinical cases. The technique was accurate and safe and no major complications were noted. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source


Terragni R.,Veterinary Oncology Center | Terragni R.,Ghent University | Gardini A.C.,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Sabattini S.,University of Bologna | And 8 more authors.
PLoS ONE | Year: 2014

Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified as a predictor of resistance to anti-EGFR drugs. In human oncology, the importance of the EGFR/HER-2/KRAS signalling pathway in gastric cancer is well established, and HER-2 testing is required before initiating therapy. Conversely, this pathway has never been investigated in canine gastric tumours. A total of 19 canine gastric epithelial neoplasms (5 adenomas and 14 carcinomas) were retrospectively evaluated for EGFR/HER-2 immunohistochemical expression and KRAS mutational status. Five (35.7%) carcinomas were classified as intestinaltype and 9 (64.3%) as diffuse-type. EGFR was overexpressed (≥1+) in 8 (42.1%) cases and HER-2 (3+) in 11 (57.9%) cases, regardless of tumour location or biological behaviour. The percentage of EGFR-positive tumours was significantly higher in the intestinal-type (80%) than in the diffuse-type (11.1%, p =0.023). KRAS gene was wild type in 18 cases, whereas one mucinous carcinoma harboured a point mutation at codon 12 (G12R). EGFR and HER-2 may be promising prognostic and therapeutic targets in canine gastric epithelial neoplasms. The potential presence of KRAS mutation should be taken into account as a possible mechanism of drug resistance. Further studies are necessary to evaluate the role of dog as a model for human gastric cancer. © 2014 Terragni et al. Source


Terragni R.,Veterinary Oncology Center | Terragni R.,Ghent University | Vignoli M.,Petcare Veterinary Association | Van Bree H.J.,Ghent University | And 2 more authors.
Schweizer Archiv fur Tierheilkunde | Year: 2014

Medical imaging is an essential part of the diagnostic workup of many gastrointestinal disorders. This paper reviews imaging and endoscopy of gastric tumors in dogs and cats and the techniques used. The appearance of the normal as well as the various aspects of gastric tumors are described for these different modalities. Plain radiography is widely available but has limited diagnostic value. Contrast radiography has higher sensitivity but is laborious and time-consuming. Ultrasonography (if an adequate acoustic window is available), endosonography and endoscopy are the most appropriate modalities for diagnosing gastric tumors. They are especially useful when obtaining samples for cytologic or histopathologic examination, because the imaging modalities do not always differentiate between infl ammatory or infectious conditions and neoplastic disorders. Hydro-helical CT was found helpful for evaluating the location and local invasive-ness of the lesion. Ultrasonography and endoscopy are useful modalities for taking adequate biopsies. © 2014 Verlag Hans Huber, Hogrefe AG, Bern. Source


Jas D.,Merial SAS | Soyer C.,Royal Veterinary College | De Fornel-Thibaud P.,Veterinary Oncology Center | Oberli F.,Merial SAS | And 4 more authors.
Trials in Vaccinology | Year: 2014

The objective of this randomised, controlled, parallel-group monocentric clinical trial was to assess the efficacy (at low and high dose) and the safety (at high dose) of a recombinant canarypox virus (ALVAC®) expressing feline interleukin 2 (IL-2). ALVAC IL-2 was administered to cats as an adjunct treatment of feline fibrosarcoma in complement to surgery and brachytherapy (reference treatment). Seventy-one cats with a first occurrence of feline fibrosarcoma were referred to the Veterinary Oncology Centre for post-surgical radiotherapy. They were randomly assigned to three treatment groups: reference treatment group (23 cats), ALVAC IL-2 low dose group (25 cats) and ALVAC IL-2 high dose group (23 cats). Two dosages of ALVAC IL-2 were used to assess both safety (high dose) and efficacy (high and low doses). The treatment consisted of six consecutive doses of ALVAC IL-2 administered subcutaneously at the tumour site on Day 0 (one day before brachytherapy treatment), Day 7, Day 14, Day 21, Day 35 and Day 49. All cats were evaluated for relapse (i.e. local tumour recurrence and/or metastasis) every three months for at least one year (ALVAC IL-2 high dose group) or two years (reference treatment and ALVAC IL-2 low dose groups) by complete physical examination and regular CT scans. ALVAC IL-2 treatment was well tolerated and adverse effects were limited to mild local reactions. ALVAC IL-2 treatment resulted in a significant longer median time to relapse (>730 days in the ALVAC IL-2 low dose group) than in the reference treatment group (287 days), and a significant reduction of the risk of relapse by 56% at one year (ALVAC IL-2 treatment groups versus reference treatment group) and 65% at two years (ALVAC IL-2 low dose treatment group versus reference treatment group). © 2014 The Authors. Published by Elsevier Ltd. Source

Discover hidden collaborations